Skip to main content

Clinical trials in the UK

There are clinical trials for Waldenstrom's macroglobulinaemia (WM) taking place throughout the UK.

Not all hospitals take part in clinical trials, however, it is worth asking your specialist about clinical trials when discussing treatment options. You do not have to take part in clinical trials and can always opt for standard treatment.

Different types of clinical trials:

  • Phase 1 trials look at how safe a treatment is
  • Phase 2 trials look at how well a treatment works in a specific group of people, for example: patients with relapsed WM. They may investigate side effects, and safe or most effective dosage levels
  • Phase 3 trials compare new treatments with standard practice
  • Phase 4 trials look at treatments that have been approved for use including: side effects and safety of the drug; what the long term risks and benefits are; and how well the drug works when it is used more widely


Patients taking part in phase 1 and 2 trials should not normally anticipate gaining any direct benefit. However, taking part in clinical trials helps to improve treatments for patients in the future.

Current trials available in the UK:

RAINBOW (up-front)

This trial looks at the incorporation of ibrutinib into frontline therapy for WM. The lead investigator is Dr Rebecca Auer at St Bartholomew’s Hospital, London. The trial aims to:

  1. Assess the toxicity and effectiveness of the ‘chemotherapy-free’ combination of rituximab and ibrutinib as a primary therapy for WM
  2. Assess whether progression-free survival is improved with rituximab and ibrutinib when compared to dexamethasone / rituximab / cyclophosphamide (DRC).

The trial is running in three centres in the UK:

  • St Bartholomew’s Hospital, London (Barts)
  • Kent and Canterbury Hospital
  • Royal Bournemouth Hospital

Pembro WM (relapse)

This trial is a phase II trial to investigate the safety and effectiveness of rituximab and pembrolizumab in relapsed/refractory WM. The lead investigator is Dr Jamail Kothari at Churchill Hospital (Oxford University Hospitals) and is open in a number of centres across the UK:

  1. University College London Hospitals
  2. Churchill Hospital, Oxford
  3. Derriford Hospital, Plymouth
  4. Royal Bournemouth Hospital
  5. St Bartholomew’s Hospital, London (Barts)

Cardinal and Cadenza Studies for Cold Agglutinin Disease (CAD)

These two ongoing studies are for patients with troublesome Cold Agglutinin Disease, resulting in anaemia or thrombosis due to so-called ‘cold haemolysis’, that may or may not require transfusions. The treatment consists of infusions of an antibody treatment called sutimlimab that targets part of the immune system called the ‘complement system’ which is instrumental in cold haemolysis.

The Cardinal study has now closed to recruitment.

The Cadenza study is still recruiting. 

Another trial of a new generation complement anti-body is due to open at University College London Hospitals (UCLH) shortly.

More information about WM trials may be available here:

Lymphoma Action (

Cancer Research UK (

US National Library of Medicine ( – this is an American site but lists worldwide trials for WM


Some trials will not be specific to WM, and it is worth looking under broader categories such as 'low grade non-Hodgkin lymphoma


Contact us for more information or advice about finding or participating in clinical trials.

Share this page

Share this page